Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2020

01-06-2020 | Magnetic Resonance Imaging | Review

Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis

Authors: Cameron B. Haas, Larissa Nekhlyudov, Janie M. Lee, Sara H. Javid, Mary Bush, Dianne Johnson, Timothy Gleason, Cary Kaufman, Jennifer Specht, Sean Stitham, Karen J. Wernli

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Login to get access

Abstract

Purpose

Women with personal history of breast cancer (PHBC) are currently recommended to receive annual mammography for surveillance of breast cancer recurrence or new primary. However, given issues in accuracy with mammography, there is a need for evolving evidence-based surveillance recommendations with supplemental imaging. In this systematic review, we compiled and compared existing studies that describe the test performance of surveillance breast MRI among women with PHBC.

Methods

We searched PubMed and EMBASE using MeSH terms for studies (2000–2019) that described the diagnostic characteristics of breast MRI in women with PHBC. Search results were reviewed and included based on PICOTS criteria; quality of included articles was assessed using QUADAS-2. Meta-analysis of single proportions was conducted for diagnostic characteristics of breast MRI, including tests of heterogeneity.

Results

Our review included 11 articles in which unique cohorts were studied, comprised of a total of 8338 women with PHBC and 12,335 breast MRI done for the purpose of surveillance. We predict intervals (PI) for cancer detection rate per 1000 examinations (PI 9–15; I2 = 10%), recall rate (PI 5–31%; I2 = 97%), sensitivity (PI 58–95%; I2 = 47%), specificity (PI 76–97%; I2 = 97%), and PPV3 (PI 16–40%; I2 = 44%).

Conclusions

Studies addressing performance of breast MRI are variable and limited in population-based studies. The summary of evidence to date is insufficient to recommend for or against use of breast MRI for surveillance among women with PHBC.
Appendix
Available only for authorised users
Literature
1.
American Cancer Society (2016) Cancer treatment & survivorship: facts & figures 2016–2017. American Cancer Society, Atlanta, p 44
2.
Howlader N et al (2016) SEER cancer statistics review, 1975–2013. National Cancer Institute, Bethesda
3.
4.
Lash TL et al (2007) Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol 25(21):3001–3006PubMedCrossRef
5.
Houssami N et al (2009) Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol 20(9):1505–1510PubMedCrossRef
6.
Lu WL et al (2009) Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 114(3):403–412PubMedCrossRef
7.
Lu W et al (2009) The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer 45(17):3000–3007PubMedCrossRef
8.
Sardanelli F et al (2016) Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey. Eur Radiol
9.
Houssami N et al (2011) Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 305(8):790–799PubMedPubMedCentralCrossRef
10.
Wernli KJ et al (2019) Surveillance breast MRI and mammography: comparison in women with a personal history of breast cancer. Radiology 292(2):311–318PubMedCrossRef
11.
Quinn EM, Coveney AP, Redmond HP (2012) Use of magnetic resonance imaging in detection of breast cancer recurrence: a systematic review. Ann Surg Oncol 19(9):3035–3041PubMedCrossRef
12.
American College of Radiology (2013) American College of Radiology (ACR) Breast Imaging Reporting and Data System Atlas (BI-RADS® Atlas). American College of Radiology (ACR), Reston
13.
14.
Liu Z et al (2013) A step-by-step guide to the systematic review and meta-analysis of diagnostic and prognostic test accuracy evaluations. Br J Cancer 108(11):2299–2303PubMedPubMedCentralCrossRef
15.
16.
Innovation VH. Covidence systematic review software
17.
Whiting PF et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536PubMedCrossRef
18.
19.
Berg WA et al (2008) Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 299(18):2151–2163PubMedPubMedCentralCrossRef
20.
Brennan S et al (2010) Breast MRI screening of women with a personal history of breast cancer. AJR Am J Roentgenol 195(2):510–516PubMedCrossRef
21.
Schacht DV et al (2014) Importance of a personal history of breast cancer as a risk factor for the development of subsequent breast cancer: results from screening breast MRI. AJR Am J Roentgenol 202(2):289–292PubMedCrossRef
22.
Cho N et al (2017) Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy. JAMA Oncol 3(11):1495–1502PubMedPubMedCentralCrossRef
23.
Elmore L, Margenthaler JA (2010) Breast MRI surveillance in women with prior curative-intent therapy for breast cancer. J Surg Res 163(1):58–62PubMedCrossRef
24.
Giess CS et al (2015) Screening breast MRI in patients previously treated for breast cancer: diagnostic yield for cancer and abnormal interpretation rate. Acad Radiol 22(11):1331–1337PubMedCrossRef
25.
Gweon HM et al (2014) Breast MR imaging screening in women with a history of breast conservation therapy. Radiology 272(2):366–373PubMedCrossRef
26.
Lehman CD et al (2016) Screening MRI in women with a personal history of breast cancer. J Natl Cancer Inst 108(3):349CrossRef
27.
Sippo DA et al (2019) Performance of screening breast MRI across women with different elevated breast cancer risk indications. Radiology 292(1):51–59PubMedCrossRef
28.
29.
Berg WA et al (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307(13):1394–1404PubMedPubMedCentralCrossRef
30.
Leeflang MM (2014) Systematic reviews and meta-analyses of diagnostic test accuracy. Clin Microbiol Infect 20(2):105–113PubMedCrossRef
31.
Rutter CM, Gatsonis CA (2001) A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 20(19):2865–2884PubMedCrossRef
32.
Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed
33.
Zwinderman AH, Bossuyt PM (2008) We should not pool diagnostic likelihood ratios in systematic reviews. Stat Med 27(5):687–697PubMedCrossRef
34.
Lee CH et al (2010) Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 7(1):18–27PubMedCrossRef
35.
Ahern CH et al (2014) Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. Br J Cancer 111(8):1542–1551PubMedPubMedCentralCrossRef
36.
Kramer S et al (1998) Magnetic resonance imaging in the diagnosis of local recurrences in breast cancer. Anticancer Res 18(3C):2159–2161PubMed
37.
Preda L et al (2006) Magnetic resonance mammography in the evaluation of recurrence at the prior lumpectomy site after conservative surgery and radiotherapy. Breast Cancer Res 8(5):R53PubMedPubMedCentralCrossRef
38.
Coulthard A, Beveridge CJ, Potterton AJ (1999) MRI in routine breast cancer follow-up: correlation with clinical outcome. Clin Radiol 54(7):459–461PubMedCrossRef
39.
Arazi-Kleinman T et al (2013) JOURNAL CLUB: is screening MRI indicated for women with a personal history of breast cancer? Analysis based on biopsy results. AJR Am J Roentgenol 201(4):919–927PubMedCrossRef
40.
Rieber A et al (1997) Value of MR mammography in the detection and exclusion of recurrent breast carcinoma. J Comput Assist Tomogr 21(5):780–784PubMedCrossRef
41.
Viehweg P et al (1998) Retrospective analysis for evaluation of the value of contrast-enhanced MRI in patients treated with breast conservative therapy. MAGMA 7(3):141–152PubMedCrossRef
42.
Cuzick J et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141PubMedCrossRef
43.
Dubsky PC et al (2012) Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 30(7):722–728PubMedCrossRef
44.
Early Breast Cancer Trialists’ Collaborative G et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716CrossRef
45.
Poggi MM et al (2003) Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 98(4):697–702PubMedCrossRef
46.
Punglia RS, Hassett MJ (2010) Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors. J Clin Oncol 28(27):4108–4110PubMedPubMedCentralCrossRef
47.
Veronesi U et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227–1232PubMedCrossRef
48.
Bassett LW et al (2008) National trends and practices in breast MRI. AJR Am J Roentgenol 191(2):332–339PubMedCrossRef
49.
Stout NK, Nekhlyudov L (2011) Early uptake of breast magnetic resonance imaging in a community-based medical practice, 2000-2004. J Womens Health (Larchmt) 20(4):631–634CrossRef
50.
51.
Khatcheressian JL et al (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24(31):5091–5097PubMedCrossRef
52.
Saslow D et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89PubMedCrossRef
53.
Mainiero MB et al (2013) ACR appropriateness criteria breast cancer screening. J Am Coll Radiol 10(1):11–14PubMedCrossRef
54.
Khatcheressian JL et al (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(7):961–965PubMedCrossRef
55.
Morrow M, Waters J, Morris E (2011) MRI for breast cancer screening, diagnosis, and treatment. Lancet 378(9805):1804–1811PubMedCrossRef
56.
Sickles EA (2010) The use of breast imaging to screen women at high risk for cancer. Radiol Clin North Am 48(5):859–878PubMedCrossRef
57.
Monticciolo DL et al (2018) Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol 15(3):408–414PubMedCrossRef
58.
Buist DSM et al (2018) Breast biopsy intensity and findings following breast cancer screening in women with and without a personal history of breast cancer. JAMA Intern Med 178(4):458–468PubMedPubMedCentralCrossRef
Metadata
Title
Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis
Authors
Cameron B. Haas
Larissa Nekhlyudov
Janie M. Lee
Sara H. Javid
Mary Bush
Dianne Johnson
Timothy Gleason
Cary Kaufman
Jennifer Specht
Sean Stitham
Karen J. Wernli
Publication date
01-06-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05637-y

Other articles of this Issue 2/2020

Breast Cancer Research and Treatment 2/2020 Go to the issue

Epidemiology

Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women

Preclinical study

Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors

Clinical trial

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

Epidemiology

Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China

Clinical trial

Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression

Epidemiology

Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits